MDxHealth SA

NasdaqCM:MDXH 주식 보고서

시가총액: US$98.4m

MDxHealth 미래 성장

Future 기준 확인 1/6

MDxHealth is forecast to grow earnings and revenue by 36.1% and 12.3% per annum respectively while EPS is expected to grow by 42.3% per annum.

주요 정보

36.1%

수익 성장률

42.3%

EPS 성장률

Biotechs 수익 성장27.1%
매출 성장률12.3%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트15 Oct 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

NasdaqCM:MDXH - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/2026108-16683
12/31/202597-22-7-35
12/31/202484-35-20-165
6/30/202481-41-25-21N/A
3/31/202475-40-27-23N/A
12/31/202370-43-27-21N/A
9/30/202364-45-30-24N/A
6/30/202355-48-35-29N/A
3/31/202346-47-34-30N/A
12/31/202237-44-38-34N/A
9/30/202230-40-32-30N/A
6/30/202225-34-28-26N/A
3/31/202223-31N/AN/AN/A
12/31/202122-29-23-23N/A
9/30/202121-28-22-21N/A
6/30/202119-28-21-21N/A
3/31/202119-28N/AN/AN/A
12/31/202018-29-21-20N/A
9/30/202015-36-20-20N/A
6/30/202011-43-20-20N/A
3/31/202011-43-21-21N/A
12/31/201912-43-22-22N/A
9/30/201917-37-25-25N/A
6/30/201922-31-28-27N/A
3/31/201925-32-29-28N/A
12/31/201828-32-30-29N/A
9/30/201831-30-30-28N/A
6/30/201833-28-31-27N/A
3/31/201837-20N/A-19N/A
12/31/201741-12N/A-10N/A
9/30/201741-9N/A-8N/A
6/30/201741-5N/A-5N/A
3/31/201736-9N/A-11N/A
12/31/201630-13N/A-17N/A
9/30/201626-15N/A-17N/A
6/30/201623-17N/A-16N/A
3/31/201620-16N/A-15N/A
12/31/201518-14N/A-14N/A
9/30/201516-14N/A-15N/A
6/30/201515-13N/A-15N/A
3/31/201513-14N/A-17N/A
12/31/201412-15N/A-19N/A
9/30/201410-16N/A-19N/A
6/30/20148-16N/A-19N/A
3/31/20148-16N/A-17N/A
12/31/20138-16N/A-14N/A

애널리스트 미래 성장 예측

수입 대 저축률: MDXH is forecast to remain unprofitable over the next 3 years.

수익 vs 시장: MDXH is forecast to remain unprofitable over the next 3 years.

고성장 수익: MDXH is forecast to remain unprofitable over the next 3 years.

수익 대 시장: MDXH's revenue (12.3% per year) is forecast to grow faster than the US market (8.9% per year).

고성장 수익: MDXH's revenue (12.3% per year) is forecast to grow slower than 20% per year.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: Insufficient data to determine if MDXH's Return on Equity is forecast to be high in 3 years time


성장 기업 발견